Praxis Precision Medicines, Inc. (PRAX)
Automate Your Wheel Strategy on PRAX
With Tiblio's Option Bot, you can configure your own wheel strategy including PRAX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PRAX
- Rev/Share 0.3857
- Book/Share 20.8595
- PB 2.5993
- Debt/Equity 0.0024
- CurrentRatio 8.4402
- ROIC -0.529
- MktCap 1104407180.0
- FreeCF/Share -7.7815
- PFCF -6.7405
- PE -5.3709
- Debt/Assets 0.0022
- DivYield 0
- ROE -0.5042
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | PRAX | Oppenheimer | -- | Outperform | -- | $97 | June 2, 2025 |
| Initiation | PRAX | Chardan Capital Markets | -- | Buy | -- | $80 | May 7, 2025 |
| Reiterated | PRAX | H.C. Wainwright | -- | Buy | $120 | $105 | March 3, 2025 |
| Initiation | PRAX | Deutsche Bank | -- | Buy | -- | $111 | Feb. 11, 2025 |
News
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies
Published: July 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
The Breakthrough Therapy Designation (BTD) was granted based on the highly compelling results from the Phase 2 EMBOLD trial in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs)
Read More
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: July 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, July 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on July 1, 2025, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 2,100 shares of its common stock to three new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment …
Read More
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: March 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on March 3, 2025, the Compensation Committee of Praxis' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 2,000 shares of its common stock and restricted stock unit awards covering an aggregate of 7,288 shares of its common stock to six new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). …
Read More
Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Praxis Precision Medicines (PRAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
About Praxis Precision Medicines, Inc. (PRAX)
- IPO Date 2020-10-16
- Website https://www.praxismedicines.com
- Industry Biotechnology
- CEO Marcio Silva De'Souza
- Employees 116